Brian Skorney comments on the Ambrx and Harpoon acquisitions, the year ahead in biotech, and his top picks Biogen, Neurocrine, and Biohaven.

Stifel's Benjamin Burnett gives his take on biotech and discusses Iovance, Cabaletta, Arcellx, Revolution, Fate, CRISPR, and Disc.

John Maraganore shares his thoughts about biotech's big achievements in 2023 and what to watch in 2024.

Ethan Perlstein describes the past and present of his rare diseases-focused company Perlara

Chris Garabedian's thoughts on the IPO market, products vs platforms, and more discipline and prioritization in biotech.

Sri Kosuri describes how Octant is using advances in biology, chemistry, multiplexing, and computing to create its platform.

Jory Bell and Nate Chang describe Playground Global's philosophy of investing in life sciences and assisting entrepreneurs.

Liisa Bayko talks about yesterdays pain data and also recent news from Alnylam, Altimmune, Caribou Biosciences, Insmed, and AN2 Therapeutics

The UC Berkeley professor and Innovative Genomics Institute director talks about the diseases that might be treated with gene editing.

Jacob Plieth shares his thoughts on MorphoSys, Syndax, Poseida, Arcellx, Autolus, Cogent, Dizal, and more.

Dr. Maus comments on CD19 lupus data, the recent FDA note on malignancies, and the work her lab is doing for brain and heme cancers.

Madeleine Armstrong shares her thoughts on CAR-T data in lupus, the menin inhibitor class, BCMA CAR-T, and Regeneron's bi-specifics.

Mara Goldstein previews key #ASH23 data from Incyte, Syndax, Autolus, Corvus, IN8bio, and more.

Greg Yap describes how his firm evaluates AI companies and lists other technology transformations to watch in the sector.

Surbhi Sarna explains how Y Combinator invests in healthcare and biotech entrepreneurs and how the application process works.

Nevan Krogan, Director of the Quantitative Biosciences Institute at UCSF, expands on work posted to bioRxiv today.

Andy Hsieh comments on AbbVie's buyout of ImmunoGen, gives a deep dive into radiopharmaceutical, and discusses AASLD, Seagen, and Icosavax.

Simeon George talks about his firm's philosophy, advice for biotech entrepreneurs, and discusses a busy few weeks of news.

Jakob Dupont says he is focused on clinical stage companies or ones that are months within IND.

Evan Seigerman discusses news from #AHA23, what's going on with Structure, Verve's polarizing result, Neurocrine, Vertex, Pfizer and more.